Alisa Lask's most recent trade in Nephros Inc was a trade of 7,050 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nephros Inc | Alisa Lask | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 7,050 | 7,050 | - | - | Stock Option (right to buy) | |
| Nephros Inc | Alisa Lask | Director | 14 May 2024 | 7,323 | 7,323 | - | - | Stock Option (right to buy) | ||
| Nephros Inc | Alisa Lask | Director | 13 Dec 2023 | 9,291 | 48,629 (0%) | 0% | 0 | Common Stock | ||
| RVL Pharmaceuticals plc | Alisa Lask | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.49 per share. | 10 Aug 2023 | 12,000 | 112,557 (0%) | 0% | 0.5 | 5,880 | Ordinary Shares |
| RVL Pharmaceuticals plc | Alisa Lask | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2023 | 40,000 | 124,557 (0%) | 0% | 0 | Ordinary Shares | |
| Nephros Inc | Alisa Lask | Director | 05 Jan 2023 | 27,613 | 39,338 (0%) | 0% | 0 | Common Stock | ||
| Nephros Inc | Alisa Lask | Director | 05 Jan 2023 | 7,080 | 7,080 | - | - | Stock Option (right to buy) | ||
| RVL Pharmaceuticals plc | Alisa Lask | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 75,000 | 84,557 (0%) | 0% | 0 | Ordinary Shares | |
| Nephros Inc | Alisa Lask | Director | 14 Dec 2021 | 7,062 | 7,062 | - | - | Stock Option (right to buy) | ||
| Nephros Inc | Alisa Lask | Director | 14 Dec 2021 | 4,582 | 11,725 (0%) | 0% | 0 | Common Stock |